Trials / Unknown
UnknownNCT03229187
Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer
Accurate Prediction and Validation of Response to Neoadjuvant Chemotherapy in Cervical Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 240 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- —
Summary
Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies. However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments. This study is undertaken to build specific molecular signatures to predict the effects of neoadjuvant chemotherapy.
Conditions
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2020-09-30
- Completion
- 2020-09-30
- First posted
- 2017-07-25
- Last updated
- 2020-06-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03229187. Inclusion in this directory is not an endorsement.